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Abstract
Background
The management of comorbidity and multimorbidity poses major challenges to health services
around the world. Analysis of scientific research in comorbidity and multimorbidity is limited in
the biomedical literature. This study aimed to map global scientific research in comorbidity and
multimorbidity to understand the maturity and growth of the area during the past decades.
Methods and findings
This was a cross-sectional analysis of the Web of Science. Searches were run from incep-
tion until November 8, 2016. We included research articles or reviews with no restrictions by
language or publication date. Data abstraction was done by one researcher. A process of
standardization was conducted by two researchers to unify different terms and grammatical
variants and to remove typographical, transcription, and/or indexing errors. All potential dis-
crepancies were resolved via discussion. Descriptive analyses were conducted (including
the number of papers, citations, signatures, most prolific authors, countries, journals and
keywords). Network analyses of collaborations between countries and co-words were pre-
sented. During the period 1970–2016, 85994 papers (64.0% in 2010–2016) were published
in 3500 journals. There was wide diversity in the specialty of the journals, with psychiatry
(16558 papers; 19.3%), surgery (9570 papers; 11.1%), clinical neurology (9275 papers;
10.8%), and general and internal medicine (7622 papers; 8.9%) the most common. PLOS
One (1223 papers; 1.4%), the Journal of Affective Disorders (1154 papers; 1.3%), the Jour-
nal of Clinical Psychiatry (727 papers; 0.8%), the Journal of the American Geriatrics Society
(634 papers; 0.7%) and Obesity Surgery (588 papers; 0.7%) published the largest number
of papers. 168 countries were involved in the production of papers. The global productivity
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ranking was headed by the United States (37624 papers), followed by the United Kingdom
(7355 papers), Germany (6899 papers) and Canada (5706 papers). Twenty authors who
published 100 or more papers were identified; the most prolific authors were affiliated with
Harvard Medical School, State University of New York Upstate Medical University, National
Taiwan Normal University and China Medical University. The 50 most cited papers (“citation
classics” with at least 1000 citations) were published in 20 journals, led by JAMA Psychiatry
(11 papers) and JAMA (10 papers). The most cited papers provided contributions focusing
on methodological aspects (e.g. Charlson Comorbidity Index, Elixhauser Comorbidity
Index, APACHE prognostic system), but also important studies on chronic diseases (e.g.
epidemiology of mental disorders and its correlates by the U.S. National Comorbidity Sur-
vey, Fried’s frailty phenotype or the management of obesity).
Conclusions
Ours is the first analysis of global scientific research in comorbidity and multimorbidity. Sci-
entific production in the field is increasing worldwide with research leadership of Western
countries, most notably, the United States.
Introduction
Over the last three to four decades, substantial progress has been made toward reducing mortality
and extending life expectancy worldwide [1,2]. Although health seems to have improved globally,
more people than ever are spending more time with functional health loss and disability [3,4]. In
many countries and regions, the management of multiple chronic diseases in a given patient at the
same time (the so-called, “comorbidity” or “multimorbidity”) poses major challenges to health ser-
vices [5–9]. People with two or more chronic (physical or mental) diseases are more likely to have
poor health outcomes, more complex clinical management and increased healthcare costs [8,9].
Analysis of scientific research in comorbidity and multimorbidity is limited in the biomedi-
cal literature [10–16]. For example, Fortin et al. [12] previously investigated the characteristics
of the publications on multimorbidity (or comorbidity) and compared the number of publica-
tions on it with the number of publications on three common chronic conditions (asthma,
hypertension, and diabetes). A restricted search of MEDLINE in 2002 identified 353 papers on
multimorbidity and comorbidity for the period 1990–2002. The number and diversity of arti-
cles were both insufficient to provide relevant data to inform evidence-based care of people
affected by multiple chronic conditions [12].
The scientific landscape has changed considerably in the subsequent years, including the
launch of important initiatives for the clinical management of multiple chronic diseases [17–
20], but also the proliferation of open-access journals to disseminate research findings [5,7,21–
25]. Considering research is needed to increase knowledge in a changing research area, this
study aimed to map global scientific research in comorbidity and multimorbidity to under-
stand maturity and growth during the past decades.
Methods
Search strategy
We conducted a cross-sectional analysis of the Web of Science, Science Citation Index-
Expanded (SCI-E) database, from inception to November 8th 2016. The Web of Science has
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been considered the world’s leading taxonomic reference for citation analysis and prior to 2004,
the only data source on citations available [26]. The search strategy for this study was designed
by two senior health information specialists (AA-A, RA-B) and a clinical epidemiologist (FC-L),
based on a previously published strategy [13]. The search strategy was constructed by using a
combination of the following terms related to comorbidity and multimorbidity (see Box 1 for
terminology): comorbidit OR co-morbidit OR multimorbidit OR multi-morbidit OR mul-
tidisease OR multi-disease OR multipatholog OR multi-patholog OR polimorbidit OR
poli-morbidit OR polipatholog OR poli-patholog OR pluripatholog OR pluri-patholog
(full strategy is available in S1 Table). We included two types of papers: research articles or
reviews on comorbidity or multimorbidity of any type (physical or mental). Meeting abstracts,
proceedings paper (journals, book-based), editorials, book chapters, corrections, retracted pub-
lications and other items (e.g. notes, news, etc. . .) were excluded. No restrictions in languages
or publication date were applied to the database search.
Box 1. Terminology
The terms of “comorbidity” and “multimorbidity” are often used interchangeably. Many
possible definitions and interpretations of the concepts of “comorbidity” and “multi-
morbidity” have been reported in the biomedical literature [9–11]. For example, Val-
deras and colleagues [9] reviewed the definitions of “comorbidity (and multimorbidity)”
and their relationship to related constructs. A brief overview of common terms follows.
Comorbidity. A widely accepted definition of “comorbidity” is the occurrence or the
existence of any distinct additional medical condition to an index disease [31]. In gen-
eral, the role of coexisting conditions is of less importance and one does not assume an
interaction between the multiple conditions. The nature of the conditions that co-occur
have variously included (physical or mental) diseases, disorders, conditions, illnesses, or
health problems. Comorbidity was first included as a MeSH term in 1989 [9,10].
Multimorbidity. Most authors define “multimorbidity” as the co-occurrence of two or
more medical conditions in an individual without any reference to an index disease
[6,9–11]. Therefore, in multimorbidity, no index disease is defined and all conditions
(or “morbidities”) are regarded of equal importance. Multimorbidity constitutes a more
generic, patient-centered concept, whereas comorbidity is an index disease-based con-
cept [11]. At present, no MeSH term exists for multimorbidity.
Some authors have introduced other terms to describe the same or closely related con-
cepts. Examples of alternative terms are: “multipathology”, “polymorbidity”, “polipathol-
ogy”, and “pluripathology” [10,13,51].
Case example. Consider a 58-year-old woman with coronary artery disease, hyperten-
sion, and major depression. Her mental health professional, focusing on the major
depression, would consider her coronary artery disease and hypertension as comorbidi-
ties. Her primary care physician might describe her as having multimorbidity, giving
equal attention to her coronary artery disease, hypertension and major depression.
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Data extraction
For each included paper, data on the year of publication, the journal title, subject category,
keywords, and the authors’ names, institutional affiliation(s), and country was downloaded
online through the SCI-E from the Web of Science by one researcher (AA-A) in November
2016. A second researcher (FC-L) verified the data to minimize potential information errors.
The SCI-E platform is a database that contains all the above information, including the full
addresses of all authors of every paper. We also used the SCI-E to determine the extent to
which each paper had been cited in the scientific peer-review literature using the “times cited”
number (that is, the number of times a publication has been cited by other publications). A
process of standardization was conducted by two researchers to bring together the different
names of an author or country, and keywords. Specifically, one researcher (AA-A) checked the
names by which an individual author appeared in two or more different forms (for example,
“Ronald C. Kessler” or “Ronald Kessler” or “Ron Kessler”), using coincidence in that author’s
place(s) of work as the basic criterion for normalization (for example, Harvard University,
United States), and a second researcher (FC-L) verified data. We used both ‘‘author keywords”
and ‘‘keyword plus,” which are automatically assigned by the Web of Science from the titles of
the references of the articles because this approach has proven to be highly effective in repre-
senting the conceptual content of articles. To ensure consistency in the data, one researcher
(RA-B) corrected keywords unifying grammatical variants and using only one keyword devel-
oped names of the same concept (for example, “diabetes mellitus” or “diabetes” or “adult dia-
betes” or “diabetes type 2” or “type 2 juvenile diabetes”). In addition, the same researcher
(RA-B) removed typographical, transcription and/or indexing errors, and a second researcher
(FC-L) verified data. All potential discrepancies were resolved via discussion. All these data
were entered into a Microsoft Access1 (Microsoft, Seattle, WA, United States) database.
Data analysis
In this paper, we analyzed data including the number of papers, citations, signatures of authors,
collaboration index (which is the mean number of author’s signatures per paper), countries,
journals and keywords. Data were summarized as frequencies and percentages for categorical
items. We have presented in tables the most prolific authors and countries (> 100 papers), and
the most cited papers (>1000 citations). We have presented network graphs (or diagrams) to
represent data visualization of the structure of the most intense scientific collaboration between
countries applying a threshold of 50 papers in collaboration. In order to depict the frequency
of the most frequently used keywords, a word cloud was created using Wordle (http://www.
wordle.net/), which is free-software that generates “word clouds” from text that the user pro-
vides and places more emphasis on words that appear with greater frequency in the source text.
We identified the most frequently used keywords per journal subject category. We also pre-
sented the “co-words network” of keywords representing the co-occurrence phenomenon of
highly frequent words in the papers. The co-words network reflects the relation among multiple
terms, and so is effective in mapping the associations between keywords in textual data [27]. We
used Pajek [28], a software package for large network analysis that is free for non-commercial
use, to construct network graphs. PRISMA checklist [29,30] (http://www.prisma-statement.org/)
guided the reporting of the present analysis (and is available in S1 Checklist).
Results
A total of 85994 papers (76350 articles and 9644 reviews) were identified and included in the
analyses (Fig 1). Table 1 details the general characteristics of the papers.
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Publication trend
The number of papers increased exponentially over the study period (Fig 2). Approximately
two-thirds of the papers have been published since 2010. The first paper was published in 1970
by Prof. Alvan R. Feinstein [31] providing the seminal definition of comorbidity referring to
“any distinct clinical entity that has co-existed or that may occur during the clinical course of a
patient who has the index disease under study.”
Journals and subject categories
3500 journals published 85994 papers. 596 (17.0%) journals published only one paper, 344 (9.8%)
journals published two, 220 (6.3%) journals published three, and 2340 (66.8%) published four or
more papers. PLOS One (n = 1223; 1.4%) and the Journal of Affective Disorders (n = 1154; 1.3%)
published the largest number of papers, followed by the Journal of Clinical Psychiatry (n = 727;
0.8%), the Journal of the American Geriatrics Society (n = 634; 0.7%) and Obesity Surgery (n = 588;
0.7%). Most papers were classified in one (n = 50354; 58.6%) or two (n = 52748; 30.7%) journal’s
subject categories. There was wide diversity in journal’s subject categories, with psychiatry, sur-
gery, clinical neurology, and general and internal medicine the most common (Table 1).
Authors and countries
Most papers were written by 4 or more authors (72.5%; n = 62311) and only 5.5% (n = 4730) of
papers were written by one author. The first authors of the papers were based most commonly
Fig 1. Selection of papers. Flowchart.
https://doi.org/10.1371/journal.pone.0189091.g001
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in North America and Europe; first authors from the United States were responsible for 38.6%
(n = 33171) of the papers (Table 1). We identified 20 authors who published 100 or more papers
(Table 2). The most prolific authors were Ronald C Kessler with 331 (from Harvard Medical
School, United States), Joseph Biederman with 248 (from Harvard Medical School, United
States), Stephen V Faraone with 227 (from State University of New York Upstate Medical Uni-
versity, United States), Chia-Hung Kao with 223 (from National Taiwan Normal University,
Taiwan) and Cheng-Li Lin with 193 papers (from China Medical University, China).
Table 1. General characteristics of the sample of study.
Characteristic Category Number Percent






















Clinical Neurology 9275 10.8
Medicine, General & Internal 7622 8.9
Cardiac & Cardiovascular Systems 5098 5.9
Country of first author (top-10)
United States 33171 38.6
Germany 5408 6.3





The Netherlands 2766 3.2
France 2737 3.2
Taiwan (Republic of China) 2034 2.4
aNovember 8th, 2016.
bSubject category according to Journal Citation Report.
https://doi.org/10.1371/journal.pone.0189091.t001
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Overall, 168 countries worldwide were involved in the sample of papers. The productivity
ranking for countries with respect to the number of papers (Table 3) was headed by the United
States (37624 papers), followed by the United Kingdom (7355 papers), Germany (6899 papers)
and Canada (5706 papers). Fig 3 shows a visual representation of the most intense collabora-
tive network between 42 countries (with at least 50 papers in co-authorship), in which we can
see the relationships of some countries with respect to others and the position that each occu-
pies in the network.
Keywords
The most commonly used article/review keywords were “comorbidity” (9223 papers; 10.7%),
followed by “depression” (n = 5853; 6.8%), “elderly” (n = 3077; 3.6%) and “mortality” (n =
2806; 3.3%) (Fig 4). The most frequently used keywords in the most common journal subject
categories are shown in Table 4. Co-words analysis shows some associations of keywords
forming triads (groupings of three terms), such as “comorbidity” and “depression” with either
“anxiety/anxiety disorders”, “posttraumatic stress disorder”, “bipolar disorder”, “alcohol
dependence”, “drug dependence” or “quality of life”; the associations of “diabetes mellitus”
with “cardiovascular diseases”, “obesity”, or “hypertension”; and the association of “depres-
sion” with “bipolar disorder” and “suicide” (Fig 5).
Most cited papers
Overall, included papers received 1.9 million citations, of which 40.9% citations (n = 808817)
corresponded to 3596 (4.2%) papers with at least 100 citations. The most cited papers by num-
ber of citations (“citation classics” with at least 1000 citations) are listed in Table 5. All the 50
most cited papers were published in English. These most cited articles were published in 20
journals, led by the Archives of General Psychiatry (now, renamed JAMA Psychiatry) with 11
Fig 2. Number of papers by year of publication. Note: Data for 2016 up to November 8th.
https://doi.org/10.1371/journal.pone.0189091.g002
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papers and followed by the Journal of the American Medical Association (JAMA) with 8 papers.
The list of most cited papers (Table 4) contains contributions dealing with methodological
aspects, but also important epidemiological studies on chronic non-communicable diseases,
comorbidity and/or multimorbidity. Some of the methodological papers present the most
commonly used measures of comorbidities in health services and outcomes research: the
“Charlson Comorbidity Index” [32,33] and its various adaptations (papers number-1, num-
ber-4, number-17 and number-20 in Table 5) and the “Elixhauser Comorbidity Index” [34]
(paper number-10). These comorbidity index measures capture the “comorbidity burden” that
Table 2. Most productive authors.














Harvard Medical School, United
States
331 81160 245.2 324 3389 10.2
Joseph
Biederman
Harvard Medical School and
Massachusetts General Hospital,
United States
248 19964 80.5 244 1685 6.8
Stephen V
Faraone
State University of New York Upstate
Medical University, United States
227 16927 74.6 226 1777 7.8
Chia-Hung Kao National Taiwan Normal University,
Taiwan (Republic of China)
223 636 2.9 223 1309 5.9
Cheng-Li Lin China Medical University Hospital,
China Medical University, China
193 550 2.8 193 1132 5.9
Murray B Stein University of California, United States 166 10590 63.8 161 1755 10.6
Hans-Ulrich
Wittchen
Dresden University of Technology,
Germany
162 24910 153.8 158 1214 7.5
Henrik Toft
Sørensen





160 19554 122.2 156 1748 10.9
Dan J Stein University of Cape Town, South
Africa
149 5773 38.7 147 1937 13.0
Kathleen Ries
Merikangas
National Institute of Mental Health
(NIMH), United States
137 15240 111.2 132 864 6.3
Fung-Chang
Sung
China Medical University, China 125 977 7.8 125 888 7.1
Jitender
Sareen
University of Manitoba, Canada 116 4146 35.7 115 617 5.3
Ron de Graaf Netherlands Institute of Mental
Health and Addiction (NIMHA),
Netherlands
114 8051 70.6 114 1331 11.7
Hagop S
Akiskal
University of California, United States 112 7029 62.8 108 748 6.7
Jordi Alonso IMIM Hospital del Mar Medical
Research Institute, Spain
111 8527 76.8 111 1717 15.5
Tzeng-Ji Chen National Yang-Ming University,
Taipei Veterans General Hospital,
Taiwan (Republic of China)
109 904 8.3 109 1051 9.6
Wayne J Katon University of Washington, United
States
107 9409 87.9 103 738 6.9
Josep M Haro Parc Sanitari Sant Joan de Déu,
Spain
105 8410 80.1 105 2712 25.8
Luigi Ferrucci National Institute on Aging (NIA),
United States
104 4307 41.4 104 927 8.9
https://doi.org/10.1371/journal.pone.0189091.t002
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United States 37624 117.1 14296 1211072 32.2 7905 146 Canada (1574)
United
Kingdom
7355 112.9 9301 186402 25.3 3669 130 United States (1336)
Germany 6899 84.7 7395 162829 23.6 2504 126 United States (999)
Canada 5706 159.2 4893 165784 29.1 2442 118 United States (1574)
Italy 5373 88.4 7094 120728 22.5 2093 122 United States (1045)
Australia 3979 167.3 3809 88132 22.2 1575 117 United States (639)
Spain 3889 83.8 5391 75487 19.4 1289 122 United States (569)
Netherlands 3885 229.4 6226 110756 28.5 1786 116 United States (728)




2173 92.4 756 23526 10.8 349 95 United States (218)
Sweden 2066 210.8 3486 53826 26.1 1167 114 United States (428)
Brazil 1978 9.5 2356 29773 15.1 658 119 United States (374)
Switzerland 1852 223.5 3659 56315 30.4 1190 118 Germany (454)
China 1735 1.3 2458 25828 14.9 693 111 United States (422)
Denmark 1689 297.6 2498 41416 24.5 798 110 United States (378)
Japan 1576 12.4 2156 29888 19.0 443 109 United States (313)
Belgium 1264 112.0 4036 36184 28.6 854 96 Netherlands (405)
Turkey 1203 15.3 983 10626 8.8 171 109 United States (88)
South Korea 1142 22.6 925 14698 12.9 288 103 United States (220)
Israel 1087 129.7 1952 26029 24.0 445 108 United States (310)
Norway 1024 197.1 1796 24185 23.6 520 107 United States (185)
Austria 1000 116.1 2577 23361 23.4 597 108 Germany (319)
Finland 923 168.4 1618 24740 26.8 403 110 United Kingdom (158)
Greece 738 68.2 1631 16008 21.7 375 112 United States (137)
Poland 664 17.5 1746 10806 16.3 276 83 United Kingdom (133)
India 652 0.5 954 9278 14.2 207 102 United States (112)
New Zealand 599 130.3 1362 23448 39.2 339 95 United States (168)
Ireland 513 110.5 1094 12680 24.7 276 94 United Kingdom (144)
Singapore 482 87.1 794 9344 19.4 219 108 United States (111)
Mexico 462 3.6 1836 17048 36.9 257 112 United States (207)
South Africa 437 8.0 1462 13692 31.3 316 113 United States (175)
Portugal 412 39.8 1406 8192 19.9 185 108 United Kingdom (92)
Hungary 295 30.0 996 7159 24.3 200 81 United States (93)
Czech
Republic
272 25.8 838 5653 20.8 142 76 Italy (53)
Iran 272 3.4 345 3210 11.8 77 105 United States (31)
Russia 242 1.7 809 6023 24.9 102 111 United Kingdom (43)
Serbia 230 32.4 482 1904 8.3 84 106 Italy (30)
Argentina 224 5.2 834 8365 37.3 115 113 United States (78)
Chile 224 12.5 416 2120 9.5 105 84 United States (56)
Saudi Arabia 220 7.0 448 4250 19.3 145 95 United States (63)
Romania 209 10.5 1273 5228 25.0 119 107 Italy (68)
Croatia 207 49.0 349 2030 9.8 62 70 Italy (22)
Thailand 184 2.7 395 1767 9.6 119 82 United States (56)
(Continued )
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exists alongside a primary diagnosis and that may influence outcomes. The list of the most
cited paper also reflects major advances in the description of the epidemiology of mental disor-
ders and its correlates by the U.S. National Comorbidity Survey [35–40] (papers number-2,
number-3, number-5, number-6, number-7 and number-15, among others in Table 5); the






















Colombia 173 3.6 1316 7497 43.3 120 109 United States (95)
Egypt 165 1.8 391 1792 10.9 87 103 United States (27)
Nigeria 165 0.9 767 5583 33.8 70 92 United States (53)
Malaysia 146 4.8 229 1322 9.1 68 83 Australia (23)
Slovenia 138 66.9 630 2770 20.1 82 78 Germany (44)
Lebanon 121 20.7 992 6770 56.0 102 98 United States (81)
Pakistan 118 0.6 431 4854 41.1 45 108 United States (23)
top-50 countries with at least 100 papers. Country inhabitants (year 2015) obtained from the World Bank (http://data.worldbank.org/).
https://doi.org/10.1371/journal.pone.0189091.t003
Fig 3. Global collaborative network between countries. Note: Most productive cluster of countries applying a threshold of 50 or more papers signed in
co-authorship. Node sizes are proportional to the number of papers and line thicknesses are proportional to the number of collaborations. Node colors:
America = red; Asia = yellow; Africa = green; Europe = blue; Oceania = purple.
https://doi.org/10.1371/journal.pone.0189091.g003
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Table 5)–the concepts of “frailty” and “comorbidity/multimorbidity” are commonly used
interchangeably to identify vulnerable older adults [42–44], but there is a growing consensus
that these might be distinct clinical entities that are causally related [42,43]; the management of
predisposing factors such as obesity and overweight [45–48] (papers number-9, number-12,
number-18 and number-33); the importance of hospital volume to operative mortality associ-
ated with cardiovascular and cancer procedures [49] (paper number-13 in Table 5); and the
development of the widely-used “Acute Physiology and Chronic Health Evaluation (APACHE)
prognostic system” [50] (paper number-14 in Table 5) to quantify the severity of illness in the
intensive care units.
Discussion
In this cross-sectional analysis, we analyzed the global scientific research in comorbidity and
multimorbidity for the period 1970–2016. We have identified the most productive investiga-
tors and countries, most common subjects and keywords, most prolific journals and “citation
classics” in comorbidity and multimorbidity based on publications in multiple specialties and
disciplines. The most striking results are the increasing number of published articles in recent
years, with approximately two-thirds of the papers published since 2010. To the best of our
knowledge, this is the first comprehensive global mapping analysis of scientific publications in
comorbidity and multimorbidity. This analysis complements and expands the perspective of
Fig 4. Word cloud for the frequency of terms. Note: Most frequently used keywords (at least 500 times).
https://doi.org/10.1371/journal.pone.0189091.g004
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Table 4. Most prolific journals and most commonly used keywords per journal subject category.






Psychiatry 16558 Journal of Affective Disorders 1154 Depression 3290
Journal of Clinical Psychiatry 727 Bipolar disorder 1295
Psychiatry Research 528 Attention deficit hyperactivity
disorder
1083
Surgery 9570 Obesity Surgery 588 Bariatric surgery 570
Journal of Vascular Surgery 489 Morbid obesity 414
Annals of Thoracic Surgery 338 Obesity 356
Clinical Neurology 9275 Journal of Affective Disorders 1154 Depression 1568
Epilepsy & Behavior 370 Bipolar disorder 727
Journal of Nervous and Mental Disease 365 Epilepsy 670
Medicine, General & Internal 7622 Medicine 302 Primary care 341
Journal of General Internal Medicine 282 Depression 326
BMJ Open 272 Diabetes mellitus 318
Cardiac & Cardiovascular
Systems
5098 Annals of Thoracic Surgery 338 Heart failure 548
American Journal of Cardiology 336 Mortality 326
International Journal of Cardiology 269 Atrial fibrillation 226
Oncology 4790 Cancer 370 Elderly 680
Journal of Clinical Oncology 279 Breast cancer 460
Annals of Surgical Oncology 154 Chemotherapy 391
Neurosciences 4698 Biological Psychiatry 249 Depression 873
Encéphale 244 Bipolar disorder 383
Bipolar Disorders 184 Attention deficit hyperactivity
disorder
311
Pharmacology & Pharmacy 4223 Drugs & Aging 236 Depression 380
Clinical Therapeutics 134 Diabetes mellitus 173
International Journal of Clinical Practice 125 Attention deficit hyperactivity
disorder
139
Urology & Nephrology 4150 Journal of Urology 331 Mortality 327
Nephrology Dialysis Transplantation 297 Prostate cancer 305
Urology 247 Hemodialysis 287
Geriatrics & Gerontology 3399 Journal of the American Geriatrics Society 634 Elderly 660
Drugs & Aging 236 Older adults 435
Archives of Gerontology and Geriatrics 203 Depression 278
Public, Environmental &
Occupational Health
3392 Medical Care 361 Depression 182
Journal of Clinical Epidemiology 220 Diabetes mellitus 160
BMC Public Health 220 Epidemiology 155
Respiratory System 3003 Annals of Thoracic Surgery 338 Chronic obstructive
pulmonary disease
622
Chest 282 Asthma 160
Respiratory Medicine 185 Mortality 155
Health Care Sciences & Services 2907 Medical Care 361 Quality of life 188
Journal of General Internal Medicine 282 Depression 154
BMC Health Services Research 245 Diabetes mellitus 148
Psychology 2788 Psychological Medicine 517 Depression 598
Depression and Anxiety 407 Epidemiology 166
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previous studies that analyzed some characteristics of articles in comorbidity [10,12], the
diversity of terms used in the literature referring to the presence of multiple concurrent dis-
eases [10,12,51], or reviews on the implications and the understanding of research needs and
treatment impact [52,53].
In line with previous research in other areas [54–57], the global productivity of scientific
papers is dominated by the United States (as a central hub of knowledge), followed by other
nodes in Western Europe (such as the United Kingdom, Germany and Italy) and Canada. The
large number of publications on comorbidity and multimorbidity from these countries reflects
Table 4. (Continued)






International Journal of Eating Disorders 249 Posttraumatic stress
disorder
144
Pediatrics 2739 Journal of the American Academy of Child and
Adolescent Psychiatry
376 Attention deficit hyperactivity
disorder
330
Pediatrics 167 Children 302
Journal of Child and Adolescent
Psychopharmacology
103 Adolescent 289
Endocrinology & Metabolism 2517 Diabetes Care 185 Diabetes mellitus 359
Obesity 137 Obesity 239
Osteoporosis International 118 Depression 122
Peripheral Vascular Disease 2446 Journal of Vascular Surgery 489 Hypertension 190
Annals of Vascular Surgery 193 Stroke 159
Circulation 192 Mortality 133
Psychology, Clinical 2429 Journal of Clinical Psychiatry 727 Depression 374
Psychological Medicine 517 Anxiety disorders 130
Depression and Anxiety 407 Eating disorders 121
Gastroenterology & Hepatology 2345 Journal of Gastrointestinal Surgery 186 Colorectal Cancer 144
World Journal of Gastroenterology 161 Mortality 112
Diseases of the Colon & Rectum 127 Hepatitis C 105
Orthopedics 2300 Spine 306 Mortality 123
Clinical Orthopaedics and Related Research 195 Risk factors 96
Journal of Bone and Joint Surgery 164 Hip fracture 95
Infectious Diseases 1792 Clinical Infectious Diseases 151 HIV infection 398
BMC Infectious Diseases 129 Mortality 146
Infection Control and Hospital Epidemiology 90 Bacteremia 104
Immunology 1691 Clinical Infectious Diseases 151 HIV infection 239
Transplantation Proceedings 134 Asthma 136
Biology of Blood and Marrow Transplantation 112 Influenza 74
Rheumatology 1610 Journal of Rheumatology 222 Rheumatoid arthritis 293
Rheumatology 132 Osteoarthritis 91
BMC Musculoskeletal Disorders 122 Gout 78
Gerontology 1597 Journal of the American Geriatrics Society 634 Elderly 660
Journals of Gerontology Series A 184 Older adults 435
International Journal of Geriatric Psychiatry 156 Depression 278
Critical Care Medicine 1589 Chest 282 Mortality 191
Critical Care Medicine 183 Intensive care 156
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the importance that Western societies devote to research as the basis for socio-economic and
technological development, but also reflects the interest in understanding and addressing
important challenges of population aging and increased complexity of chronicity. Ageing of the
world’s population is increasing the number of people living with sequelae of multiple diseases,
with an increasing trend in low-income countries [1–4]. As might be expected, the scientific
community captured is centered on a nucleus of scientists and researchers from academia, med-
ical and health research centers from North America and Western Europe, but also from Aus-
tralia and Taiwan (Republic of China). Specifically, the most intense global collaborations took
place between authors and institutions from the United States, the United Kingdom and Can-
ada. Perhaps, the very limited participation of low and middle income-based researchers and
institutions in research on comorbidity and multimorbidity could warrant further pragmatic
action given that the epidemiological transition (e.g. replacement of infectious diseases by
chronic diseases) imposes more constraints to deal with the burden of multiple chronic diseases
in a poor environment characterized by ill-health systems [3,4,58–60].
Papers on comorbidity and multimorbidity were published most often in journals devoted
to neuropsychiatry and neurosciences. Psychiatry has become one of the fastest growing medi-
cal disciplines [61]. In fact, the publication activity and interest of comorbidity and multimor-
bidity in people with mental disorders seems to be increasing [62,63]. Our analysis revealed
that nearly 20% of all scientific production was published in journals belonging to psychiatry
and mental health. This large relative productivity in psychiatry may be explained by the
important role of comorbidity and its implications for theories of etiology, prevention and
treatment of mental disorders [63]. Within psychiatry, comorbidity has been traditionally
Fig 5. Co-words network of the author keywords. Node sizes are proportional to the number of papers and line thicknesses are proportional to the
number of co-occurrences of words. Node colors: blue = words related to general terms; green = words related to diseases/disorders, signs and symptoms;
yellow = interventions.
https://doi.org/10.1371/journal.pone.0189091.g005
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used to refer to the overlap of two or more psychiatric disorders [64]. Similarly, comorbidity
(and multimorbidity) between mental disorders and substance use disorders [65–67], cardio-
vascular diseases [68–70], cancer [71,72] or other chronic disorders [6,73] has gained promi-
nence within the past few decades.
Our analyses suggest that other medical disciplines with a large number of papers on
comorbidity and multimorbidity, including surgery [74,75], clinical neurology [76–78], gen-
eral and internal medicine [3,4,79,80], cardiology [81] and oncology [82], focus on those con-
ditions with a high global burden of disease. The subject analysis has revealed that the
keywords’ prioritization in comorbidity and multimorbidity depends on the addressed subject
area. For example, “Depression” is the most commonly used keyword in the subject categories
of Psychiatry, Clinical Neurology, Neurosciences, Psychology; but also in General and Internal
Medicine, Geriatrics and Gerontology, Pharmacology, Endocrinology, Public, Environmental
and Occupational Health, and Health Care Sciences and Services. Depression is a common
mental disorder that occurs in people of all ages across all world regions and represents a lead-
ing cause of disease burden [3,4,78]. Despite existing evidence of the effectiveness of multiple
interventions, traditional approaches to the management of the depressive disorders (such as
medication alone and brief psychotherapy) have contributed to large treatment gaps [83–86].
In this respect, the complex pathogenesis implicates factors of diverse nature that should be
considered in research. For example, integrating the management of depressive disorders with
other common mental disorders (e.g. anxiety disorders and bipolar disorder) or other chronic
conditions (e.g. cancer, diabetes and diseases of the cardiorespiratory system) through trans-
diagnostic interventions [83].
The topic analysis of the most cited papers (“citation classics”) allowed us to determine
which topics have attracted the most interest in the research on comorbidity and multimorbid-
ity. These include landmark methodological developments in measuring comorbidity (such as
Charlson’s index, Elixhauser’s index and their modifications) [32–34] and descriptive epidemi-
ological studies measuring the burden of comorbidity [35–40], among others. However,
important knowledge gaps in comorbidity and multimorbidity remain. The limitations of clin-
ical practice guidelines and treatment for single diseases are well recognized in the biomedical
literature, along with the call to make better use of the best evidence base [87,88]. Clinical trials
are usually conducted in homogeneous populations, which prevents us from knowing whether
treatment effects in people with multiple chronic diseases are equivalent to those in patients
with single diseases [89,90]. The evidence base for interventions to improve outcomes for peo-
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generated to support disease management policies in primary care and community settings
[53]. The consideration of people with multimorbidity is essential in future study design and
evaluations of health services and technologies. To be of value, it is important that research
includes the evaluation of the benefits of multiple approaches for multiple coexisting diseases
(e.g. patient-, family- and population-centered), and that generalizability and applicability
problems be explicitly addressed [87–91].
There are several limitations to our study. We characterized knowledge structures gener-
ated by papers included in the Web of Science database, integrating subject categories of jour-
nals, keywords of papers and network analyses. However, these methods represent a scoping
approach which could be complemented further by more detailed analyses, for example ana-
lyzing the content and reporting quality of papers in evidence syntheses (including systematic
reviews of the literature [92]). We only analyzed research articles and review articles. Undoubt-
edly, there are other important reports (e.g. health policy reports, meeting abstracts and let-
ters/correspondence [93]) that also merit consideration in global debates and discussions in
comorbidity and multimorbidity. The validity of keywords mapping and the results of the co-
word analyses depend on the definitions of words chosen to conceptualize the papers by the
authors or database indexers to categorize papers. The growing interest in comorbidity and
multimorbidity by health care providers has resulted in more research on these issues, which
may have led to a proliferation of different terms for the same concepts. For example, the tradi-
tional (and widely accepted) term “comorbidity” is associated with high volume of papers but
may lack specificity, whereas the more recently introduced term of “multimorbidity” is associ-
ated with low number of papers (see S1 Table). As Almirall and Fortin stated “[t]he use of
clearly defined terms in the literature is recommended until a general consensus on the termi-
nology of multiple coexistent diseases is reached” across multiple disciplines [51]. Given the
dynamic nature of the field, it will be interesting to see whether the growth trend remains in
the coming years, and how the characteristics of the field changes of time (e.g. by means of lon-
gitudinal network analyses).
Conclusion
The global analysis presented in this study provides compelling evidence of the scientific
growth of research on comorbidity and multimorbidity. Scientific research in this field is
increasingly published in biomedical journals, with research leadership of Western countries,
most notably, the United States. This study contributes to a better understanding in this chal-
lenging field and identifies the main areas of research, the publication sources chosen for their
scientific dissemination and the major scientific leaders. Advances in several subjects and
research areas will allow for use of new theories and models to fundamentally changes in the
management of people with multiple chronic diseases.
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